This content is in French.
Prebiotics alone are not enough to treat non-alcoholic fatty liver disease
26 juin 2024
Non-alcoholic fatty liver disease (NAFLD) is a common liver disease that often progresses to more serious conditions such as fibrosis and cirrhosis of the liver. There is a strong association between this disease and metabolic syndrome.
Alteration of the gut microbiota has been suggested as a factor contributing to the development and progression of NAFLD.
Here, this randomised, double-blind, placebo-controlled clinical trial explores whether administration of prebiotics can influence liver fat content and other metabolic and inflammatory parameters in patients with NAFLD.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Reshef N, Gophna U, Reshef L, Konikoff F, Gabay G, Zornitzki T, Knobler H, Maor Y. Prebiotic Treatment in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)-A Randomized Pilot Trial. Nutrients. 2024 May 22;16(11):1571. doi: 10.3390/nu16111571. PMID: 3
View on PubMed
